Biolyst › ALTAltimmune, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 46.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 18 concluded trials, 89% reached completion rather than being terminated or withdrawn.
Track ALT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ALT in the tracker
Recent history
Date Event Type Phase
September 29, 2026
8-K filed: Leadership change Corporate
—
August 12, 2026
Quarterly results filed (8-K) Earnings
—
July 30, 2026
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Trial Milestone
Phase 2
July 28, 2026
8-K filed: Reg FD disclosure, Other event Filing
—
June 16, 2026
8-K filed: Other event Filing
—
May 13, 2026
Quarterly results filed (8-K) Earnings
—
April 24, 2026
8-K filed: Material agreement Corporate
—
March 5, 2026
Quarterly results filed (8-K) Earnings
—
February 3, 2026
8-K filed: Other event Filing
—
January 28, 2026
8-K filed: Material agreement Corporate
—
December 19, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
December 1, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
November 25, 2025
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) Trial Milestone
Phase 2
November 6, 2025
Quarterly results filed (8-K) Earnings
—
November 6, 2025
8-K filed: Material agreement Corporate
—
October 3, 2025
8-K filed: Leadership change Corporate
—
August 12, 2025
Quarterly results filed (8-K) Earnings
—
June 26, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
May 13, 2025
Quarterly results filed (8-K) Earnings
—
March 27, 2024
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) Trial Milestone
Phase 2
September 28, 2023
Efficacy and Safety of ALT-801 in the Treatment of Obesity Trial Milestone
Phase 2
February 3, 2023
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) Trial Milestone
Phase 1
October 31, 2022
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) Trial Milestone
Phase 1
August 17, 2022
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Trial Milestone
Phase 1
May 15, 2022
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers Trial Milestone
Phase 1
December 1, 2021
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) Trial Milestone
Phase 1
October 29, 2021
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability Trial Milestone
Phase 1
March 15, 2021
NasoShield in Healthy Adults to Study Safety and Immunogenicity Trial Milestone
Phase 1
February 15, 2021
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Trial Milestone
Phase 2
May 13, 2019
NasoShield Study of Safety and Immunogenicity Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.